SION (Sionna Therapeutics) Total Liabilities: $16.83 Mil (As of Mar. 2026)


SION Sionna Therapeutics Inc SION
12 GF Score
Price $43.99
! 3 Warning Signs
View Full Analysis

What is Sionna Therapeutics Total Liabilities?

Sionna Therapeutics SION +5.64% 12 Total Liabilities is $16.83 Mil as of Mar. 2026. GuruFocus rates SION with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

Sionna Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $16.83 Mil.

Sionna Therapeutics's quarterly Total Liabilities increased from Sep. 2025 ($17.60 Mil) to Dec. 2025 ($19.12 Mil) but then declined from Dec. 2025 ($19.12 Mil) to Mar. 2026 ($16.83 Mil).

Sionna Therapeutics's annual Total Liabilities increased from Dec. 2023 ($166.83 Mil) to Dec. 2024 ($349.47 Mil) but then declined from Dec. 2024 ($349.47 Mil) to Dec. 2025 ($19.12 Mil).

Sionna Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Sionna Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sionna Therapeutics Total Liabilities Chart

Sionna Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Liabilities
157.29 166.83 349.47 19.12

Sionna Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 17.91 15.62 17.60 19.12 16.83
SION
12GF Score
Sionna Therapeutics Inc SION
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sionna Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Sionna Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=11.712+(7.408+8.8817841970013E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=19.12

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=325.953-306.833
=19.12

Sionna Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=9.776+(7.055+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=16.83

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=305.039-288.208
=16.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $16.83 Mil mean?
Sionna Therapeutics (SION) has a Total Liabilities of $16.83 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Sionna Therapeutics and its competitors.
Is Sionna Therapeutics' Total Liabilities too high?
Sionna Therapeutics' current Total Liabilities is $16.83 Mil. Overall, Sionna Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sionna Therapeutics' Total Liabilities compare to TYRA and RAPP?
Sionna Therapeutics' Total Liabilities of $16.83 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Sionna Therapeutics and its competitors. Sionna Therapeutics's current Total Liabilities is $16.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sionna Therapeutics stock overvalued right now?
Sionna Therapeutics (SION) has a current Total Liabilities of $16.83 Mil. The current Total Liabilities is $16.83 Mil. Sionna Therapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Sionna Therapeutics (SION), the current Total Liabilities is $16.83 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sionna Therapeutics Business Description

Address 21 Hickory Drive, Suite 500, Waltham, MA, USA, 02451
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
12GF Score

Get the complete analysis for SION

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$43.99
Price